Study of Pasireotide for Prolactinoma
Part of Hormones & metabolism clinical trials.
This trial tests a drug called pasireotide for people with prolactinoma (a type of pituitary tumor) who cannot use standard dopamine agonist medicines or whose tumors do not shrink enough with them. It may be an option if surgery isn't right for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a prolactinoma tumor and cannot take dopamine agonists (like cabergoline) because of side effects, another medical reason, or the tumor/ prolactin levels did not respond well enough.
- Surgery is not a good option for you (due to health risks, tumor location, or personal choice).
- Your blood counts, liver and kidney function are within certain safe limits.
- You are able to care for most of your daily needs (Karnofsky score 70 or higher).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares medicine (bromocriptine) and surgery for people with a certain type of pituitary tumor (prolactinoma) that has not spread too far. It aims to see which approach works best and is safest for you.
This trial tests if switching from a standard somatostatin analog to pasireotide can better control acromegaly in patients whose growth hormone and IGF-1 levels remain high. It aims to offer a more effective treatment option for those not responding well enough to initial therapy.
This trial tests a higher dose of the drug cabergoline to see if it works better for small prolactin-secreting tumors (microprolactinomas) in premenopausal women who have not been treated before. It aims to find a safe and effective way to lower high prolactin levels and shrink the tumor.
This trial studies how pasireotide LAR—a drug that controls growth hormone levels—affects bone health in people with acromegaly whose disease is not well-controlled after 6 months of another therapy. It may help patients understand the bone benefits of switching to this treatment.
This study looks at how changes in estrogen before diagnosis affect the growth of prolactin-secreting pituitary tumors (prolactinomas). The goal is to understand why some tumors are larger than others.
This trial tests a drug called pasireotide as a maintenance therapy (given after standard treatment to keep cancer from coming back) for people with specific types of sarcoma. It's for patients whose tumors show high levels of certain proteins (SSTR) and who have stable or better disease after standard treatment.
Hear when a new Prolactin-Producing Pituitary Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.